NASDAQ$OSUR
OraSure Technologies Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
OraSure Technologies, Inc. reported its financial results for the fourth quarter ended December 31, 2024.
OraSure Technologies reported a 51% decrease in total net revenues for Q4 2024, primarily due to a significant decline in COVID-19 revenues. Despite this, core revenues showed a 10% year-over-year growth, indicating a gradual recovery in key end markets and diversification efforts.
- Total net revenues for Q4 2024 decreased 51% to $37.4 million, primarily driven by the decline in COVID-19 revenues.
- Core revenues (excluding COVID-19 and Molecular Services) increased 10% year-over-year to $36.5 million in Q4 2024.
- The company reported a GAAP operating loss of $12.4 million in Q4 2024, compared to an operating income of $3.9 million in Q4 2023.
- Cash and cash equivalents stood at $267.8 million as of December 31, 2024, with $5.0 million deployed for the acquisition of Sherlock Biosciences during the quarter.
Headline financials
Revenue & EPS history
OraSure · Revenue · Quarterly
$37.4M
Forward guidance
OraSure Technologies is guiding for Q1 2025 revenues between $27.5 million and $31.5 million, with core revenues expected to be $27 million to $31 million, including approximately $1 million from Risk Assessment testing revenues. COVID-19 revenues are projected to be around $0.5 million.
Tailwinds
- Anticipated continued growth in core revenues, reflecting ongoing diversification and recovery in key markets.
- Strategic acquisition of Sherlock Biosciences expected to expand innovation pipeline with an advanced molecular platform.
- FDA approval for OraQuick® HIV Self-Test labeling change to include adolescents, broadening access to testing.
- Award received for the development of a Marburg Virus Disease rapid antigen test, indicating new revenue streams and public health contributions.
- Continued support for Risk Assessment customers while winding down remaining inventory, streamlining operations.
Headwinds
- Overall revenue guidance for Q1 2025 is lower than Q4 2024, primarily due to the continued decline in COVID-19 revenues.
- Elevated uncertainty related to government funding sources for some existing customers.
- Completion of the largest government contract earlier in 2024 significantly impacts COVID-19 revenue.
- The molecular diagnostics platform from Sherlock Biosciences is subject to FDA approval, introducing regulatory risk.
- Winding down the Risk Assessment testing business will result in a decrease in revenue from this segment.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-2.1%
Avg return
Earnings day
+0.4%
Avg return
5 days after
-2.4%
Avg return
30 days after
39%
25 / 64 earnings
Positive
+31.7%
Q2 2023
Best reaction
-32.1%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -2.9% | — | |
| Q4 2025 | +10.0% | +6.4% | +7.1% | |
| Q3 2025 | -6.6% | -4.3% | -3.1% | |
| Q1 2025 | -6.8% | -5.0% | +3.6% | |
| Q4 2024 | -23.5% | -10.8% | -14.2% | |
| Q3 2024 | -1.2% | -1.2% | -8.9% | |
| Q2 2024 | +2.6% | -0.2% | +5.7% | |
| Q1 2024 | -8.8% | -6.9% | -15.3% | |
| Q4 2023 | +10.3% | +3.7% | -12.3% | |
| Q3 2023 | +4.9% | +14.5% | +22.2% | |
| Q2 2023 | +31.7% | +43.9% | +42.8% | |
| Q1 2023 | +9.2% | -20.8% | -22.3% | |
| Q4 2022 | +10.4% | +18.8% | +30.1% | |
| Q3 2022 | +0.7% | +20.8% | +18.5% | |
| Q2 2022 | +28.3% | +38.6% | +18.8% | |
| Q1 2022 | -8.9% | -3.9% | -48.8% | |
| Q4 2021 | -1.3% | -0.8% | -13.0% | |
| Q3 2021 | -4.9% | -7.7% | -19.8% | |
| Q2 2021 | +1.2% | -0.7% | -4.1% | |
| Q1 2021 | +5.0% | +5.1% | +0.2% | |
| Q4 2020 | -2.3% | +2.1% | +1.5% | |
| Q3 2020 | -15.6% | -15.4% | -20.6% | |
| Q2 2020 | -32.1% | -24.6% | -46.9% | |
| Q1 2020 | +6.1% | +15.6% | -33.1% | |
| Q4 2019 | -6.7% | -6.1% | +8.5% | |
| Q3 2019 | -3.1% | -6.9% | -10.3% | |
| Q2 2019 | -3.3% | -5.2% | -14.4% | |
| Q1 2019 | -8.0% | -12.6% | -12.7% | |
| Q4 2018 | -25.5% | -18.3% | -14.8% | |
| Q3 2018 | -8.7% | -6.6% | -15.0% | |
| Q2 2018 | -0.6% | -1.0% | -5.8% | |
| Q1 2018 | -15.4% | -11.0% | -2.4% | |
| Q4 2017 | -12.8% | -13.4% | -9.5% | |
| Q3 2017 | -30.3% | -26.6% | -13.8% | |
| Q2 2017 | +13.5% | +19.4% | +17.4% | |
| Q1 2017 | +16.9% | +10.9% | +17.6% | |
| Q4 2016 | +18.9% | +18.9% | +29.9% | |
| Q3 2016 | -0.1% | +1.4% | +14.3% | |
| Q2 2016 | +4.6% | +8.5% | +30.7% | |
| Q1 2016 | -6.6% | — | — | |
| Q4 2015 | +14.7% | — | — | |
| Q3 2015 | +0.4% | — | — | |
| Q2 2015 | +7.0% | — | — | |
| Q1 2015 | -12.3% | — | — | |
| Q4 2014 | -11.9% | — | — | |
| Q3 2014 | +2.9% | — | — | |
| Q2 2014 | -7.7% | — | — | |
| Q1 2014 | -9.2% | — | — | |
| Q4 2013 | +9.5% | — | — | |
| Q3 2013 | -0.3% | — | — | |
| Q2 2013 | +10.2% | — | — | |
| Q1 2013 | -0.4% | — | — | |
| Q4 2012 | -12.4% | — | — | |
| Q3 2012 | -16.4% | — | — | |
| Q2 2012 | -7.1% | — | — | |
| Q1 2011 | +5.0% | — | — | |
| Q1 2012 | -5.9% | — | — | |
| Q4 2011 | +4.6% | — | — | |
| Q3 2011 | -5.6% | — | — | |
| Q4 2010 | -12.5% | — | — | |
| Q2 2011 | -12.5% | — | — | |
| Q3 2010 | +6.6% | — | — | |
| Q2 2010 | -7.0% | — | — | |
| Q1 2010 | -15.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro